Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis

Sponsor
Assiut University
Study ID
NCT07209644
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

This study investigates the relationship between serum catestatin levels and systemic sclerosis (SSc), with a focus on cardiovascular involvement and microvascular alterations, to determine catestatin's potential as a biomarker of disease activity and severity.

Key Dates

Start date
Nov 1, 2026
Status verified
Sep 2025
Primary completion
Nov 1, 2027
Completion
Dec 1, 2027

Study Design

Enrollment
70 participants (estimated)

Arms

  • Arm: Systemic Sclerosis Arm
    Patients with systemic sclerosis (n=35), assessed for disease activity, catestatin levels, cardiovascular involvement, and microvascular changes.
  • Arm: Control Arm
    Healthy controls (n=35), evaluated for serum catestatin levels to provide a baseline reference.

Primary Outcome Measure

change in level of serum catestatin concentration in systemic sclerosis patients compared with healthy controls. [ Time Frame: baseline ]

Related Studies